São Paulo - Delayed Quote • BRL Novo Nordisk A/S (N1VO34.SA) Follow Compare 65.63 +0.44 +(0.67%) At close: January 10 at 6:05:00 PM GMT-3 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for N1VO34.SA 1D 5D -2.25% 1M -22.39% 3M -19.81% 6M -30.99% YTD -2.73% 1Y 0.31% 5Y 160.70% All 160.70% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: N1VO34.SA View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations 4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025 Pharma Stock Roundup: FDA Updates for JNJ, GSK, PFE, NVO's Expanded Deal Eli Lilly (LLY) Vs Novo Nordisk (NVO): Which is the Best Weight Loss Stock for 2025? Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy LLY Falls Around 14% in 3 Months: How to Play the Stock Is Eli Lilly Stock A Buy Or A Sell After Its Weight-Loss Drug Scores A Major Victory? 5 questions facing pharma in 2025 Novo Nordisk and Valo expand cardiometabolic drug partnership Less than 50% of employers cover GLP-1 drugs for weight loss: JPM survey Novo Nordisk Received an Upgrade from UBS for Its Ozempic and Wegovy's Strong Brand Recognition